Glucocorticoids improve high‑intensity exercise performance in humans
ISSN:
1439-6319DOI:
10.1007/s00421-013-2784-7Date:
2014Abstract:
Purpose: It was investigated whether oral dexamethasone (DEX) administration improves exercise performance by reducing the initial rate of muscle fatigue development during dynamic exercise. Methods: Using a double-blinded placebo controlled randomized crossover design, subjects ingested either 2 × 2 mg of DEX or placebo for five consecutive days. Muscle function was investigated using one-legged kicking exercise and whole body performance was evaluated using a 20-m shuttle run and a 30-m sprint test. Results: One-legged dynamic knee-extensor exercise time to exhaustion was 29 ± 35% (mean ± SD) longer (P < 0.05) in DEX compared to Placebo. Likewise, total running distance in the shuttle run test was 19 ± 23% longer (P < 0.05), whereas 30-m sprint performance was unaltered. During the initial 75 s of dynamic leg extensions, peak force and rate of force development determined from an electrically evoked twitch declined in a similar way in DEX and placebo. Similarly, the EMG root mean square was similar with DEX and placebo treatment. Conclusion: Short-term dexamethasone administration increases high-intensity one-legged kicking time to exhaustion and 20-m shuttle run performance, although sprint ability and the initial loss of muscular force generating capacity are similar after DEX and placebo.
Purpose: It was investigated whether oral dexamethasone (DEX) administration improves exercise performance by reducing the initial rate of muscle fatigue development during dynamic exercise. Methods: Using a double-blinded placebo controlled randomized crossover design, subjects ingested either 2 × 2 mg of DEX or placebo for five consecutive days. Muscle function was investigated using one-legged kicking exercise and whole body performance was evaluated using a 20-m shuttle run and a 30-m sprint test. Results: One-legged dynamic knee-extensor exercise time to exhaustion was 29 ± 35% (mean ± SD) longer (P < 0.05) in DEX compared to Placebo. Likewise, total running distance in the shuttle run test was 19 ± 23% longer (P < 0.05), whereas 30-m sprint performance was unaltered. During the initial 75 s of dynamic leg extensions, peak force and rate of force development determined from an electrically evoked twitch declined in a similar way in DEX and placebo. Similarly, the EMG root mean square was similar with DEX and placebo treatment. Conclusion: Short-term dexamethasone administration increases high-intensity one-legged kicking time to exhaustion and 20-m shuttle run performance, although sprint ability and the initial loss of muscular force generating capacity are similar after DEX and placebo.
En abierto se puede consultar la versión aceptada del documento.
En abierto se puede consultar la versión aceptada del documento.
Collections
Files in this item



